相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
T. Yamazaki et al.
CELL DEATH AND DIFFERENTIATION (2014)
Checkpoint blocking antibodies in cancer immunotherapy
Chrisann Kyi et al.
FEBS LETTERS (2014)
Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses
Andrew Zloza et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of colon cancer after resection
Wei Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus
Anna Kanerva et al.
CLINICAL CANCER RESEARCH (2013)
HMGB1 in Cancer: Good, Bad, or Both?
Rui Kang et al.
CLINICAL CANCER RESEARCH (2013)
[18F]-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Response Evaluation of Oncolytic Adenovirus Treatments of Patients with Advanced Cancer
Anniina Koski et al.
HUMAN GENE THERAPY (2013)
Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells
Anna Fialova et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients
Yvonne Nadine Fahmueller et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy
Christin Wittwer et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica
Akiyuki Uzawa et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients
Ilkka Liikanen et al.
MOLECULAR THERAPY (2013)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo et al.
NATURE MEDICINE (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy
Oliver J. Stoetzer et al.
TUMOR BIOLOGY (2013)
Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients
Weiling He et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2013)
Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy
Tao Li et al.
BJU INTERNATIONAL (2012)
Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus
Iulia Diaconu et al.
CANCER RESEARCH (2012)
Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
Sari Pesonen et al.
CANCER RESEARCH (2012)
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors
Sari Pesonen et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer
Otto Hemminki et al.
MOLECULAR THERAPY (2012)
SPECT/CT Imaging of hNIS - Expression after Intravenous Delivery of an Oncolytic Adenovirus and 131I
Maria Rajecki et al.
PLOS ONE (2012)
In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments
Sophie Escutenaire et al.
ANNALS OF MEDICINE (2011)
Oncolytic adenovirus based on serotype 3
O. Hemminki et al.
CANCER GENE THERAPY (2011)
Knockdown of HMGB1 in Tumor Cells Attenuates Their Ability To Induce Regulatory T Cells and Uncovers Naturally Acquired CD8 T Cell-Dependent Antitumor Immunity
Zuqiang Liu et al.
JOURNAL OF IMMUNOLOGY (2011)
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Alan Melcher et al.
MOLECULAR THERAPY (2011)
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
Vincenzo Cerullo et al.
MOLECULAR THERAPY (2011)
HMGB1 and RAGE in Inflammation and Cancer
Gary P. Sims et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients
Vincenzo Cerullo et al.
CANCER RESEARCH (2010)
Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
Petri Nokisalmi et al.
CLINICAL CANCER RESEARCH (2010)
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors
S. Pesonen et al.
GENE THERAPY (2010)
MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors
Matthias Leisegang et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
Anniina Koski et al.
MOLECULAR THERAPY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas
Guoqiang Bao et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Omental Milky Spots Develop in the Absence of Lymphoid Tissue-Inducer Cells and Support B and T Cell Responses to Peritoneal Antigens
Javier Rangel-Moreno et al.
IMMUNITY (2009)
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
James F. Curtin et al.
PLOS MEDICINE (2009)
High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease
T. Hoshina et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2008)
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
IMMUNOLOGICAL REVIEWS (2007)
Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: A major nosologic difference with adult tumors
J Vakkila et al.
CLINICAL CANCER RESEARCH (2006)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE UROLOGY (2005)
Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects
L Burdelya et al.
JOURNAL OF IMMUNOLOGY (2005)
分享论文
